CardioNet (BEAT) Approved for 15th U.S. Patent
More News related to BEAT
- CardioNet (BEAT) volatility low; shares near record low
- Brean Murray Downgrades CardioNet (BEAT) to Hold; Lowers Estimates
- CardioNet, Inc. Reports Third Quarter 2009 Financial Results
- CardioNet (BEAT) Updates Mobile Cardio Telemetry Reimbursement Info
- CardioNet, Inc. Provides Update on Mobile Cardiovascular Telemetry Reimbursement
CardioNet, Inc. (NASDAQ: BEAT) announced today that the U.S. Patent and Trademark office has granted patent number 7,587,237 to CardioNet. The patent includes certain systems and techniques utilized by the Company's Mobile Cardiac Outpatient Telemetry (MCOT) system that automatically processes complex physiological information to make it useful for clinical decisions.
This is the 15th U.S. Patent that has been issued to CardioNet.
Patent number 7,587,237 is the "Biological Signal Management" patent, which states: Systems and techniques for managing biological signals. In one implementation, a method includes receiving a cardiac biological signal that includes information describing events, determining a merit of each event based on one or more of a severity of a cardiac condition associated with the event and a quality of the event, and handling a subset of the events that meet a merit criterion. The subset can be handled for medical purposes.
Related Categories
Corporate NewsStocks Mentioned
-0.18Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
